1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
DAB-Supported Small Business Grants is sponsored by National Institute on Aging (NIA), Division of Aging Biology (DAB). This program supports small business grants for research and development of new diagnostic tools, methods, biomarkers, therapeutics, imaging devices, and technologies to monitor, diagnose, predict, prevent, treat, and further the understanding of the molecular mechanisms of agin…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small business concerns. Confirm the full requirements in the official notice before applying.
The current listing shows up to $700,000 in Phase I and $3 Million in Phase II for AD/ADRD projects; up to $500,000 in Phase I and $2.5 Million in Phase II for other projects. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was September 5, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
DAB-Supported Small Business Grants is funded by National Institute on Aging (NIA), Division of Aging Biology (DAB). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
The National Institute on Aging's FY 2026 AD/ADRD portfolio consolidates the dementia research infrastructure layer — NCRAD, NACC, the new AI and Technology Collaboratory Coordinating Center — into a small number of large, often single-source cooperative agreements. The $113M new-research increment goes elsewhere. For investigators submitting in FY 2026, the structural change matters more than the headline dollar number.
Read articleSeven research teams will run the first clinical trials aimed at extending human healthspan under ARPA-H PROSPR contracts worth up to $144M. The milestone-based contract model breaks every convention of federal biomedical funding.
Read articleARPA-H PROSPR program funds seven research teams up to $144M to develop the first clinical trials targeting biological aging itself, testing rapamycin analogs, semaglutide, and retrotransposon inhibitors.
Read article